| Nov 15 |
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...
|
| Nov 14 |
Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 13 |
Biofrontera GAAP EPS of -$0.98 misses by $0.15, revenue of $9M misses by $1.01M
|
| Nov 13 |
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 12 |
Earnings Outlook For Biofrontera
|
| Nov 1 |
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
|
| Oct 31 |
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
|
| Oct 23 |
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc
|
